Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.66 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | NCF1 | P14598 | 1/20 | 0.62 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.61 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12687 | 0.98 | HRH3 (0.78) | HRH3ALDH1A1LMNAPOLBCXCR4 | |
| SCHEMBL329323 | 0.98 | HRH3 (0.78) | HRH3ALDH1A1LMNAPOLBCXCR4 | |
| Hydrochloric Acid SCHEMBL6968666 | 0.96 | HRH3 (0.75) | HRH3ALDH1A1LMNAPOLBCXCR4 | |
| SCHEMBL1046331 | 0.95 | ALDH1A1 (0.70) | HRH3ALDH1A1LMNAPOLBCXCR4 | |
| SCHEMBL13215736 | 0.95 | ALDH1A1 (0.70) | HRH3ALDH1A1LMNAPOLBCXCR4 | |
| SCHEMBL1045984 | 0.93 | ALDH1A1 (0.74) | HRH3ALDH1A1LMNAPOLBCXCR4 | |
| SCHEMBL1045595 | 0.93 | ALDH1A1 (0.74) | HRH3ALDH1A1LMNAPOLBCXCR4 | |
| SCHEMBL7989530 | 0.91 | LMNA (0.83) | HRH3ALDH1A1LMNAPOLBCXCR4 | |
| SCHEMBL11356824 | 0.91 | LMNA (0.83) | HRH3ALDH1A1LMNAPOLBCXCR4 | |
| SCHEMBL1045922 | 0.91 | LMNA (0.83) | HRH3ALDH1A1LMNAPOLBCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4463452-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | LUNAC THERAPEUTICS LTD (GB) | 2024-09-05 | — | — | US | disclosed |
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023177700-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-3515449-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2022-05-26 | — | — | US | disclosed |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| EP-1318172-B1 | Pneumatic tire having a rubber component containing a tin/amino functionalized rubber and an inversion carbon black | GOODYEAR TIRE & RUBBER (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20040254301-A1 | Conjugated diolefin (co)polymer rubber, process for producing (co)polymer rubber, rubber composition, composite, and tire | JSR CORPORATION (JP) | 2004-12-16 | — | — | US | disclosed |
| US-6821964-B2 | FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH MONOCYTE ACCUMULATION, LYMPHOCYTE ACCUMULATION OR LEUCOCYTE ACCUMULATION | PFIZER INC | 2004-11-23 | — | — | US | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
| EP-1457501-A1 | CONJUGATED DIOLEFIN POLYMER RUBBER PROCESS FOR PRODUCING POLYMER RUBBER RUBBER COMPOSITION COMPOSITE AND TIRE | JSR Corporation (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-0924227-B1 | Conjugated diolefin-based copolymer rubber and composition thereof | JSR CORP (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-20030125448-A1 | A butadiene-styrene copolymer having end terminals modified with a tin compound and amino compound; molecular weight distribution, tire rolling resistance, hysteresis-free, wear resistance | GOODYEAR TIRE & RUBBER COMPANY, THE | 2003-07-03 | — | — | US | disclosed |
| EP-1318172-A1 | Pneumatic tire having a rubber component containing a tin/amino functionalized rubber and an inversion carbon black | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6191234-B1 | CONJUGATED DIENE-AROMATIC VINYL COPOLYMER OBTAINED BY MODIFYING POLYMER WITH A AMINO GROUP IS USED TO IMPROVE WET SKID RESISTANCE, WEAR RESISTANCE OF AUTOMOBILE TIRE TREAD | JSR CORPORATION (JP) | 2001-02-20 | — | — | US | disclosed |
| EP-0924227-A1 | Conjugated diolefin-based copolymer rubber and composition thereof | JSR Corporation (JP) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F7 | HRH3 2335/4885ALDH1A1 3635/4885LMNA 564/4885 |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | HRH3 4842/4885ALDH1A1 4471/4885LMNA 1344/4885 |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | HRH3 1767/4885ALDH1A1 2897/4885LMNA 599/4885 |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | HRH3 4842/4885ALDH1A1 4471/4885LMNA 1344/4885 |
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL15, IL2 | HRH3 951/4885ALDH1A1 482/4885LMNA 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.